A Phase 1, First-in-human Study of Safety, Tolerability, and Pharmacokinetics of VX-668
Latest Information Update: 19 Mar 2024
At a glance
- Drugs VX 668 (Primary)
- Indications Alpha 1-antitrypsin deficiency
- Focus Adverse reactions; First in man
- Sponsors Vertex Pharmaceuticals
Most Recent Events
- 13 Mar 2024 Status changed from recruiting to completed.
- 26 Feb 2024 Planned End Date changed from 1 Jan 2024 to 1 Feb 2024.
- 03 Mar 2023 Status changed from not yet recruiting to recruiting.